Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Altria

Morgan Stanley

Monday's U.S. issuance of investment-grade corporate bonds was the highest since mid May, not counting the day after Labor Day.

Companies Are Racing to Tap the Bond Market. Why They Suddenly Want to Issue Debt.

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Prices $4.5 Billion of Senior Unsecured Notes.

Bristol Myers Squibb Prices $4.5 Billion of Senior Unsecured Notes

Chevron

Microsoft

AbbVie

Advanced Micro Devices

Comcast

Cisco Systems

Datadog

L3Harris

Southwest Airlines

Newell Brands

ON Semiconductor

Sanofi

Valley National

Vertex Pharmaceuticals

Western Digital

Here are some of the tickers on Jim's radar for Monday, Oct. 30, taken directly from his reporter's notebook:

Here are 16 stocks Jim Cramer is watching, including Microsoft, Chevron, Southwest

Karyopharm Therapeutics

—  Phase 1b/2 Trial Will Investigate Mezigdomide in Combination with  Selinexor  in Patients with Relapsed/Refractory Multiple Myeloma Progressing after T-cell Immunotherapies – — Expected to be Initiated 1H 2024 – NEWTON, Mass. , Oct. 30, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has entered into a clinical trial collaboration and supply agreement with Bristol-Myers Squibb (NYSE: BMY) to evaluate the company's proprietary investigational cereblon E3 ligase modulator (CELMoD™) agent mezigdomide in combination with Karyopharm's selinexor, an approved first-in-class inhibitor of Exportin 1 (XPO1), plus dexamethasone in patients with relapsed/refractory multiple myeloma.

Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for.

European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

Shares of Bristol Myers Squibb (BMY) fell Thursday after the company reported that sales of the drug maker's popular Revlimid blood cancer treatment plunged due to competition from generics.

Bristol Myers Squibb Revenue Falls on Generic Competition for Key Drug

Bristol-Myers' (BMY) third-quarter 2023 earnings and sales beat estimates as Opdivo and new products offset losses due to oncology drug Revlimid's generic erosion.

Bristol-Myers (BMY) Q3 Earnings & Sales Beat, Opdivo Sales Grow

Honeywell

In the preliminary Q3 GDP print, consumer spending jumped to +4.0% while private domestic investment roared ahead +8.4%.

Q3 GDP +4.9%, Earnings Beats for UPS, Bristol Myers and Honeywell

Bristol-Myer Squibb Company (NYSE:BMY ) Q3 2023 Earnings Conference Call October 26, 2023 8:00 AM ET Company Participants Giovanni Caforio - Chairman, Chief Executive Officer Chris Boerner - Chief Operating Officer David Elkins - Executive Vice President, Chief Financial Officer Adam Lenkowsky - Chief Commercialization Officer Sarnit Hirawat - Chief Medical Officer Tim Power - Vice President, Investor Relations Conference Call Participants Chris Schott - JP Morgan Geoff Meacham - Bank of America Luisa Hector - Berenberg Seamus Fernandez - Guggenheim Chris Shibutani - Goldman Sachs Steven Scala - TD Cowen Terence Flynn - Morgan Stanley Evan Siegerman - BMO Capital Markets Carter Gould - Barclays Andrew Baum - Citi Tim Anderson - Wolfe Research David Risinger - Leerink Partners Robyn Karnauskas - Truist Mohit Bansal - Wells Fargo Olivia Brayer - Cantor Fitzgerald Sean - Raymond James Operator Hello and welcome to the Bristol-Myers Squibb third quarter 2023 earnings conference call. All participants will be in listen-only mode.

Bristol-Myers Squibb (BMY) Q3 2023 Earnings Call Transcript

Bristol Myers Squibb pushed back sales expectations for its new drugs by a year early Thursday, and BMY stock tumbled.

Bristol Myers Skids After Pushing Back A Key $10 Billion Sales Milestone

Bristol Myers Squibb (BMY) came out with quarterly earnings of $2 per share, beating the Zacks Consensus Estimate of $1.76 per share. This compares to earnings of $1.99 per share a year ago.

Bristol Myers Squibb (BMY) Surpasses Q3 Earnings and Revenue Estimates

Shares of Bristol-Myers Squibb Co (NYSE:BMY) dropped 4% in pre-market trading, erasing nearly $5 billion from the pharmaceutical company's market value. It came after the drugmaker announced a one-year delay in its target to achieve $10 billion in sales from its new-product portfolio.

Bristol Myers Squibb shares drop 4% premarket after it resets expectations

Bristol-Myers Squibb Co. BMY, +0.87% on Thursday posted net income of $1.928 billion, or 93 cents a share, for the third quarter, up from $1.606 billion, or 75 cents a share, in the year-earlier period. Adjusted per-share earnings came to $2.00, ahead of the $.176 FactSet consensus.

Bristol-Myers Squibb earnings top estimates

Bristol Myers Squibb's revenue was in line with estimates, but fell slightly from the same period last year due to lower sales of blood cancer drug Revlimid.

Bristol Myers Squibb earnings top estimates even as top-selling drug fights generic competition

Drugmaker Bristol Myers Squibb on Thursday pushed back by a year the time frame for its current new-product portfolio to hit $10 billion in sales as the ramp-up of new drugs including anemia treatment Reblozyl, psoriasis drug Sotyktu, and multiple sclerosis drug Zeposia takes longer than expected.

Bristol Myers says it needs another year to hit target for new drugs

CVS Health

Shares of CVS Health and Bristol Myers Squibb are down more than 20% year to date. Both businesses, however, have some promising growth opportunities ahead.

2 Absurdly Cheap Healthcare Stocks to Buy and Hold for Decades

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports Third Quarter Financial Results for 2023.

Bristol Myers Squibb Reports Third Quarter Financial Results for 2023

American Electric Power Company

Enterprise Products Partners

Eversource Energy

Evergy Inc

Home Depot

Lowe's

NextEra Energy

SPDR S&P 500 ETF Trust

Tractor Supply

In this series, I rank a selection of Dividend Radar stocks and present the ten top-ranked stocks for further research and possible investment. I screened for high-quality stocks with superior growth and income prospects this month. Additionally, I screened for stocks trading below my risk-adjusted Buy Below prices. Of the 713 Dividend Radar stocks, only 18 survived this month's stringent screens.

10 Dividend Growth Stocks For October 2023

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis.

Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis

Investors are likely to focus on Opdivo's demand along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q3 results.

What's in Store for Bristol-Myers (BMY) in Q3 Earnings?

Mirati Therapeutics

Bristol Myers Squibb is a large pharmaceutical company with a strong dividend yield and impressive assets. The company's recent acquisition of Mirati Therapeutics, including its oncology drug Krazati, is expected to support long-term shareholder returns. Mirati Therapeutics has a promising pipeline of drugs, including MRTX1719, and potential expanded indications that could increase sales.

Bristol-Myers Squibb Acquisition Of Mirati Makes Sense

Chesapeake Energy

Civitas Resources

EOG Resources

TipRanks' analyst ranking service pinpoints Wall Street's best-performing stocks, including Cisco and Chesapeake Energy.

Top Wall Street analysts favor these five dividend stocks during tumultuous times

Buying Bristol-Myers now could be a practical application of Buffett's advice to be greedy when others are fearful. As it stands right now, the pharmaceutical giant is highly concentrated on just three mega-blockbuster products. However, that will almost certainly change with time. Bristol-Myers is a financial fortress with an A+ credit rating and an easily covered 4% dividend yield.

Bristol-Myers Squibb: Time To Get Greedy

Bristol Myers' (BMY) subcutaneous formulation of Opdivo, developed using Halozyme's Enhanze technology, meets noninferiority goals in a late-stage kidney cancer study compared with intravenous Opdivo.

Bristol Myers' (BMY) Opdivo SC Meets Kidney Cancer Study Goals

Johnson & Johnson

Eli Lilly

McKesson

Pfizer

Procter & Gamble

Walgreens

This hasn't been a great year for healthcare stocks. The Dow Jones U.S. Health Care Index is down 4% on the year compared to a 14% gain in the S&P 500 index.

News for Bristol-Myers Stock (BMY)